BACKGROUND Bioresorbable everolimus-eluting scaffolds (BVS) and metallic drug-eluting stents with bioabsorbable polymers (MBP-DES) have shown positive clinical results in studies. Direct comparative evaluation between both for the process of endothelialization is lacking and could be relevant to define their safety profile and subsequently estimate the appropriate duration of dual antiplatelettherapy. In this study we sought to evaluate endothelialization of BVS and MBP-DES, implanted both in same patient, with OCT performed at 6 and 12 months.
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METHODS Multicenter (16 centers) prospective study. Patients were recruited when requiring stent implantation (without overlapping) in at least two separate lesions of similar morphologic characteristics. Each lesion was randomized to be treated with a BVS or a MBP-DES (Synergy TM, Orsiro TM or Biomatrix TM). After the procedure patients were scheduled alternatively for 6 or 12 months evaluation with optical coherence tomography. Co-primary endpoints are % of uncovered struts at 6 and 12 months. RESULTS Up to date 100 patients have been included all treated in at least one lesion with a BVS and in at least other lesion with a MBP-DES (50% Synergy TM, 25% Orsiro TM and 25% Biomatrix TM). Among these, 20 patients have been so far examined with OCT at 6 months. The proportion of uncovered struts was 2.8 AE 2.4 % with MBP-DES and 3.2 AE 3.8 % with BVS (p¼0.4) and the proportion of malapposed struts was 2.2 AE 2.8 % and 2 AE 3.7% respectively (p¼0.7). Maximal malapposition area was 1 AE 1.3 mm2 with MBP-DES and 1.8 AE 2.4 mm2 with BVS (p¼0.1). Evaginations or protusion of covered struts were more common with BVS.
CONCLUSIONS Pending of final follow up and analysis of the whole cohort, at 6 months the proportion of uncovered struts is very low and comparable between bioresorbable everolimus-eluting scaffolds and metallic drug-eluting stents with bioabsorbable polymers. Differences in evagination and malapposition magnitude could be observed. METHODS A total of 109 consecutive stable angina patients treated with overlapping BRS (May 2012-July 2014) and 149 patients treated with overlapping new generation EES (January 2011 and July 2014) in 2 Italian centers were included. Exclusion criteria included bifurcation lesions treated with a 2-stents/scaffolds strategy and patients with end stage renal failure. After propensity matching, a total of 70 stable angina patients treated with overlapping BRS and 70 patients treated with overlapping new generation EES were included. The primary outcomes were angiographic and procedural success. Secondary endpoints included 1-year rate of major adverse cardiovascular events (MACE: defined as the composite of all-cause mortality, non-procedural myocardial infarction (MI) and target-vessel revascularization).
CATEGORIES CORONARY: Bioresorbable Vascular Scaffolds
RESULTS Post procedural acute gain was significantly lower in patients treated with BRS (1.82AE0.66mm versus 2.03AE0.68mm, p¼0.033). Angiographic success (BRS vs. EES: 94.3% vs. 95.5%, p¼0 .742), rates of periprocedural MI (BRS vs. EES: 7.1% vs. 5.7%, p¼0.730) and procedural success (BRS vs. EES: 88.6% vs. 89.9%, p¼0.854) were similar between the two groups. At 1-year follow up, the estimated MACE rate was not significantly different between the two groups (BRS vs. EES: 14.5% vs. 15.9%; P log-rank ¼0.427). Similarly, no significant differences were seen in 1-year rates of TVR (BRS vs. EES: 11.7% vs. 8.1%, P log-rank ¼0.8), TLR (BRS vs. EES: 7.5% vs. 6.5%, P log-rank ¼0.917) or follow-up MI (BRS vs. EES: 0% vs. 0%, P log-rank ¼0.098). No cases of definite stent thrombosis were observed in the two groups.
CONCLUSIONS This small propensity matched study demonstrated that treating long lesions with overlapping scaffolds is feasible and safe with acceptable procedural outcomes. Even though there was a significantly lower acute gain in the BRS group compared to EES, this did not translate into worse clinical outcomes. Future, large randomized trials are needed to assess the clinical performance of BRS compared to new generation EES in patients implanted with overlapping scaffolds. 
